	US 11,773,182 B2
	Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
Cyril Barinka, Vestec (CZ); Martin G. Pomper, Baltimore, MD (US); Zora Novakova, Vestec (CZ); and Catherine A. Foss, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US); and Institute of Biotechnology CAS, V.V.I., Vestec (CZ)
Appl. No. 16/475,805
Filed by The Johns Hopkins University, Baltimore, MD (US); and Institute of Biotechnology CAS, V.V.I., Vestec (CZ)
PCT Filed Jan. 5, 2018, PCT No. PCT/US2018/012530 § 371(c)(1), (2) Date Jul. 3, 2019, PCT Pub. No. WO2018/129284, PCT Pub. Date Jul. 12, 2018.
Claims priority of provisional application 62/442,482, filed on Jan. 5, 2017.
Prior Publication US 2019/0330367 A1, Oct. 31, 2019
Int. Cl. A61K 39/00 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); A61K 51/10 (2006.01); G01N 33/574 (2006.01); A61K 39/395 (2006.01)

CPC C07K 16/3069 (2013.01) [A61K 47/68 (2017.08); A61K 49/0032 (2013.01); A61K 49/0058 (2013.01); A61K 51/1072 (2013.01); G01N 33/57434 (2013.01); A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/92 (2013.01)]

18 Claims

1. An isolated antibody or antigen-binding antibody fragment thereof that specifically binds to human prostate specific membrane antigen (PSMA) and that comprises a heavy chain comprising SEQ ID NO: 7 and a light chain comprising SEQ ID NO: 6.